secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amylyx Pharmaceuticals, Inc. (AMLX)
CIK:        0001658551
Form:       8-K
Filed at:   2024-12-30T23:59:59+00:00
Accession:  0001193125-24-286212
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 7.01
LLM model:  deepseek-v4-flash:cloud@v2

Amylyx and Gubra collaborate on GLP-1 antagonist; milestones up to >$50M
------------------------------------------------------------------------

- Collaboration with Gubra to develop a novel long-acting GLP-1 receptor antagonist; Amylyx to make small upfront and research payments (not material).
- Gubra eligible for >$50M in success-based development and commercialization milestones plus mid-single digit royalties.
- Amylyx expects cash runway into 2026; upfront and research payments not material to the company.
- Screening to identify lead development candidate for IND-enabling studies; Amylyx has option to lead development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658551/000119312524286212/0001193125-24-286212-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658551/000119312524286212/d920512d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-286212

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer